Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant decline in short interest during the month of April. As of April 30th, there was short interest totaling 413,675 shares, a decline of 55.4% from the April 15th total of 926,778 shares. Based on an average daily volume of 1,653,442 shares, the short-interest ratio is currently 0.3 days. Currently, 6.6% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Avalon GloboCare in a report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Avalon GloboCare Stock Performance

Shares of NASDAQ:ALBT opened at $0.34 on Friday. The stock has a market capitalization of $2.84 million, a price-to-earnings ratio of -0.10 and a beta of -0.04. The stock’s 50-day simple moving average is $0.52 and its two-hundred day simple moving average is $1.00. Avalon GloboCare has a 52-week low of $0.21 and a 52-week high of $4.74.

Avalon GloboCare (NASDAQ:ALBT) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.49) EPS for the quarter.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.